AR107041A1 - Inhibidores de la tirosina kinasa de bruton y métodos de su uso - Google Patents

Inhibidores de la tirosina kinasa de bruton y métodos de su uso

Info

Publication number
AR107041A1
AR107041A1 ARP160103788A ARP160103788A AR107041A1 AR 107041 A1 AR107041 A1 AR 107041A1 AR P160103788 A ARP160103788 A AR P160103788A AR P160103788 A ARP160103788 A AR P160103788A AR 107041 A1 AR107041 A1 AR 107041A1
Authority
AR
Argentina
Prior art keywords
6alkyl
group
6alq
6haloalkyl
phenyl
Prior art date
Application number
ARP160103788A
Other languages
English (en)
Spanish (es)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR107041A1 publication Critical patent/AR107041A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ARP160103788A 2015-12-10 2016-12-12 Inhibidores de la tirosina kinasa de bruton y métodos de su uso AR107041A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562265780P 2015-12-10 2015-12-10

Publications (1)

Publication Number Publication Date
AR107041A1 true AR107041A1 (es) 2018-03-14

Family

ID=57681785

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103788A AR107041A1 (es) 2015-12-10 2016-12-12 Inhibidores de la tirosina kinasa de bruton y métodos de su uso

Country Status (16)

Country Link
US (3) US10689396B2 (enExample)
EP (1) EP3386992B1 (enExample)
JP (2) JP7110097B2 (enExample)
KR (1) KR20180094514A (enExample)
CN (2) CN113105475B (enExample)
AR (1) AR107041A1 (enExample)
AU (1) AU2016366546B2 (enExample)
BR (1) BR112018011525B1 (enExample)
CA (1) CA3007993C (enExample)
EA (1) EA038031B1 (enExample)
IL (1) IL259862B (enExample)
JO (1) JO3793B1 (enExample)
MX (1) MX386700B (enExample)
TW (1) TWI739779B (enExample)
UY (1) UY37016A (enExample)
WO (1) WO2017100668A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3003987B2 (ja) 1996-08-20 2000-01-31 篠▲崎▼ 晴彦 合成樹脂管内に施設されるケーブルの支持装置及びそのケーブル支持具を取付ける方法
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
EP3596087A1 (en) * 2017-03-15 2020-01-22 Janssen Sciences Ireland Unlimited Company Methods of selective aryl- and heteroaryl-nitrogen bond formation
CN110028525A (zh) * 2018-04-13 2019-07-19 太仓运通新材料科技有限公司 一种2-氟磷酰基乙酸三乙酯的合成方法
IL278291B2 (en) 2018-05-17 2023-10-01 Forma Therapeutics Inc Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
LT3860989T (lt) * 2018-10-05 2023-06-12 Forma Therapeutics, Inc. Sulieti pirolinai, kurie veikia kaip ubikvitinui specifinės proteazės 30 (ups30) inhibitoriai
TW202039512A (zh) 2018-12-06 2020-11-01 日商第一三共股份有限公司 環烷-1,3-二胺化合物
WO2021043200A1 (zh) * 2019-09-04 2021-03-11 正大天晴药业集团股份有限公司 一种喹唑啉衍生物的制备方法及其结晶
CN111635368B (zh) * 2020-06-12 2021-06-29 东莞市东阳光仿制药研发有限公司 一种胺化合物的制备方法
CN114478346A (zh) * 2021-12-31 2022-05-13 和鼎(南京)医药技术有限公司 一种制备乌帕替尼中间体的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3112415A1 (de) 1981-03-28 1982-10-07 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden
US5430150A (en) 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5300478A (en) 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
EP1789055A4 (en) 2004-09-15 2009-11-11 Janssen Pharmaceutica Nv INHIBITORS OF THIAZOLOPYRIDINE KINASE
US7579356B2 (en) 2005-05-04 2009-08-25 Janssen Pharmaceutica Nv Thia-tetraazaacenaphthylene kinase inhibitors
WO2007019191A2 (en) 2005-08-08 2007-02-15 Janssen Pharmaceutica, N.V. Thiazolopyrimidine kinase inhibitors
WO2007092879A2 (en) * 2006-02-08 2007-08-16 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
DK2529622T3 (en) 2006-09-22 2018-05-07 Pharmacyclics Llc INHIBITORS OF BRUTON-TYROSINKINASE
US8598174B2 (en) * 2008-11-12 2013-12-03 Genetech, Inc. Pyridazinones, method of making, and method of use thereof
WO2011133609A2 (en) 2010-04-19 2011-10-27 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of btk inhibitors
FR2978441A1 (fr) 2011-07-25 2013-02-01 Diverchim Nouveaux analogues de ceramides, leurs procedes de preparation et leurs applications dans les compositions pharmaceutiques et cosmetiques
AU2014230935A1 (en) 2013-03-15 2015-09-03 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
ES2678021T3 (es) * 2013-12-11 2018-08-08 Biogen Ma Inc. Compuestos de biarilo útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
WO2018103058A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018103060A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use

Also Published As

Publication number Publication date
CN113105475A (zh) 2021-07-13
US20190284203A1 (en) 2019-09-19
US10800792B2 (en) 2020-10-13
JP2022141851A (ja) 2022-09-29
MX2018007084A (es) 2018-11-09
CA3007993A1 (en) 2017-06-15
JO3793B1 (ar) 2021-01-31
EP3386992B1 (en) 2019-11-27
US20190284204A1 (en) 2019-09-19
UY37016A (es) 2017-06-30
CN109071563A (zh) 2018-12-21
BR112018011525A2 (pt) 2018-11-21
MX386700B (es) 2025-03-19
CA3007993C (en) 2024-01-16
CN113105475B (zh) 2022-09-09
EA201891379A1 (ru) 2018-12-28
US10689396B2 (en) 2020-06-23
AU2016366546B2 (en) 2021-08-12
IL259862A (en) 2018-07-31
TWI739779B (zh) 2021-09-21
TW201734020A (zh) 2017-10-01
JP7471348B2 (ja) 2024-04-19
JP7110097B2 (ja) 2022-08-01
JP2018536684A (ja) 2018-12-13
EA038031B1 (ru) 2021-06-25
US20170283431A1 (en) 2017-10-05
AU2016366546A1 (en) 2018-05-31
KR20180094514A (ko) 2018-08-23
BR112018011525B1 (pt) 2023-10-24
WO2017100668A1 (en) 2017-06-15
IL259862B (en) 2022-04-01
US10822348B2 (en) 2020-11-03
EP3386992A1 (en) 2018-10-17

Similar Documents

Publication Publication Date Title
AR107041A1 (es) Inhibidores de la tirosina kinasa de bruton y métodos de su uso
AR107042A1 (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
AR100438A1 (es) Pirazolopiridinas y pirazolopirimidinas
AR092253A1 (es) Inhibidores de serina/treonina cinasa
PE20190326A1 (es) Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas
AR109810A1 (es) 1h-imidazo[4,5-b]piridin-2(3h)-onas sustituidas y uso de estas como moduladores del receptor glun2b
AR110405A1 (es) Compuestos
AR106118A1 (es) Compuestos bicíclicos como inhibidores de atx
ES2721031T3 (es) Compuestos de dihidroisoquinolinona sustituidos
AR109295A1 (es) Compuestos tricíclicos que contienen nitrógeno y usos de los mismos en medicina
AR112086A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
MX2016015544A (es) Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1.
AR090292A1 (es) Compuestos basados en pirazolo[1,5-a]pirimidina, composiciones que los comprenden y metodos que los utilizan
AR090220A1 (es) Inhibidores de serina/treonina cinasa
AR094857A1 (es) Derivados de pirrolo[2,3-d]pirimidina
AR088449A1 (es) Benzilindazoles sustituidos
AR091023A1 (es) Inhibidores del nampt
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
PH12019502425A1 (en) Crystalline forms of a jak inhibitor compound
AR109296A1 (es) Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat)
AR113790A1 (es) Amidas de imidazopiridina sustituidas y su uso
PE20211246A1 (es) Compuestos biciclicos para su uso como inhibidores de rip1 quinasa
AR109651A1 (es) Compuestos de piridina y pirazina como inhibidores de ripk2
AR102825A1 (es) Derivados heterocíclicos de amida activos como plaguicidas con sustituyentes que contienen azufre

Legal Events

Date Code Title Description
FB Suspension of granting procedure